Vestal Point Capital
Latest statistics and disclosures from Vestal Point Capital's latest quarterly 13F-HR filing:
- Top 5 stock holdings are INSM, JAZZ, CYTK, NARI, ACLX, and represent 31.59% of Vestal Point Capital's stock portfolio.
- Added to shares of these 10 stocks: INSM (+$62M), NARI (+$50M), AGIO (+$34M), BMRN (+$28M), AVDL (+$26M), GPCR (+$26M), BHVN (+$25M), KALV (+$20M), EW (+$18M), DAWN (+$17M).
- Started 25 new stock positions in ITCI, BRKR, EW, BDX, AGIO, ARDX, LEGN, GILD, AVDL, TENX.
- Reduced shares in these 10 stocks: ASND (-$75M), JAZZ (-$67M), GMED (-$62M), RARE (-$58M), BGNE (-$50M), , APLT (-$36M), CYTK (-$30M), SLNO (-$24M), AXSM (-$24M).
- Sold out of its positions in ALXO, APLS, AXSM, BGNE, BNTX, DNLI, DYN, EXAS, FULC, GMED. IMNM, INSP, IOVA, PCRX, PRAX, NAMS.
- Vestal Point Capital was a net seller of stock by $-126M.
- Vestal Point Capital has $1.3B in assets under management (AUM), dropping by -1.68%.
- Central Index Key (CIK): 0001974915
Tip: Access up to 7 years of quarterly data
Positions held by Vestal Point Capital consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Vestal Point Capital
Vestal Point Capital holds 69 positions in its portfolio as reported in the September 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Insmed Com Par $.01 (INSM) | 8.9 | $117M | +113% | 1.6M | 73.00 |
|
| Jazz Pharmaceuticals Shs Usd (JAZZ) | 7.6 | $100M | -40% | 900k | 111.41 |
|
| Cytokinetics Com New (CYTK) | 6.0 | $79M | -27% | 1.5M | 52.80 |
|
| Inari Medical Ord (NARI) | 4.8 | $64M | +342% | 1.6M | 41.24 |
|
| Arcellx Common Stock (ACLX) | 4.3 | $56M | 675k | 83.51 |
|
|
| Structure Therapeutics Sponsored Ads (GPCR) | 3.8 | $51M | +105% | 1.2M | 43.89 |
|
| Kalvista Pharmaceuticals (KALV) | 3.5 | $46M | +73% | 4.0M | 11.58 |
|
| Astria Therapeutics (ATXS) | 3.3 | $44M | +23% | 4.0M | 11.01 |
|
| Immatics NV SHS (IMTX) | 3.2 | $43M | +36% | 3.8M | 11.41 |
|
| Ultragenyx Pharmaceutical (RARE) | 3.2 | $42M | -58% | 750k | 55.55 |
|
| Ascendis Pharma A/S Sponsored Adr (ASND) | 2.8 | $37M | -66% | 250k | 149.31 |
|
| Soleno Therapeutics (SLNO) | 2.8 | $36M | -40% | 720k | 50.49 |
|
| Day One Biopharmaceuticals I (DAWN) | 2.6 | $35M | +100% | 2.5M | 13.93 |
|
| Savara (SVRA) | 2.6 | $34M | +24% | 8.1M | 4.24 |
|
| Agios Pharmaceuticals (AGIO) | 2.6 | $34M | NEW | 760k | 44.43 |
|
| Xenon Pharmaceuticals (XENE) | 2.5 | $33M | +57% | 825k | 39.37 |
|
| BioMarin Pharmaceutical (BMRN) | 2.1 | $28M | NEW | 400k | 70.29 |
|
| Avadel Pharmaceuticals Com Shs Put Option (AVDL) | 2.0 | $26M | NEW | 2.0M | 13.12 |
|
| Biohaven Call Option (BHVN) | 1.9 | $25M | NEW | 500k | 49.97 |
|
| uniQure NV SHS (QURE) | 1.8 | $23M | 4.8M | 4.93 |
|
|
| Janux Therapeutics (JANX) | 1.7 | $22M | -33% | 485k | 45.43 |
|
| Black Diamond Therapeutics (BDTX) | 1.7 | $22M | +139% | 5.0M | 4.35 |
|
| Solid Biosciences Com New (SLDB) | 1.5 | $20M | +5% | 2.8M | 6.97 |
|
| Edwards Lifesciences (EW) | 1.4 | $18M | NEW | 275k | 65.99 |
|
| Gilead Sciences (GILD) | 1.3 | $17M | NEW | 200k | 83.84 |
|
| Liquidia Corp Com New (LQDA) | 1.1 | $15M | -18% | 1.5M | 10.00 |
|
| Agilent Technologies Inc C ommon (A) | 1.1 | $15M | NEW | 100k | 148.48 |
|
| Bristol Myers Squibb (BMY) | 1.0 | $13M | -50% | 250k | 51.74 |
|
| GSK Sponsored Adr (GSK) | 0.9 | $12M | NEW | 300k | 40.88 |
|
| Bicara Therapeutics | 0.8 | $11M | NEW | 425k | 25.47 |
|
| Dianthus Therapeutics (DNTH) | 0.8 | $11M | -34% | 395k | 27.38 |
|
| Crinetics Pharmaceuticals In (CRNX) | 0.8 | $11M | NEW | 205k | 51.10 |
|
| Iteos Therapeutics (ITOS) | 0.8 | $11M | -41% | 1.0M | 10.21 |
|
| Applied Therapeutics (APLT) | 0.7 | $9.7M | -78% | 1.1M | 8.50 |
|
| Nurix Therapeutics (NRIX) | 0.7 | $9.5M | -15% | 425k | 22.47 |
|
| Sanofi SA Sponsored Adr (SNY) | 0.7 | $8.6M | NEW | 150k | 57.63 |
|
| Bruker Corporation (BRKR) | 0.7 | $8.6M | NEW | 125k | 69.06 |
|
| Apogee Therapeutics (APGE) | 0.6 | $8.0M | NEW | 137k | 58.74 |
|
| Zymeworks Del (ZYME) | 0.6 | $7.7M | +39% | 615k | 12.55 |
|
| Lexeo Therapeutics (LXEO) | 0.6 | $7.7M | 850k | 9.04 |
|
|
| Tarsus Pharmaceuticals (TARS) | 0.6 | $7.6M | NEW | 230k | 32.89 |
|
| Alto Neuroscience Com Shs (ANRO) | 0.6 | $7.4M | +4% | 650k | 11.44 |
|
| Becton, Dickinson and (BDX) | 0.5 | $7.2M | NEW | 30k | 241.10 |
|
| Madrigal Pharmaceuticals (MDGL) | 0.5 | $6.4M | NEW | 30k | 212.22 |
|
| Legend Biotech Corp Sponsored Ads (LEGN) | 0.5 | $6.1M | NEW | 125k | 48.73 |
|
| Fate Therapeutics (FATE) | 0.4 | $5.9M | -15% | 1.7M | 3.50 |
|
| Galapagos NV Spon Adr (GLPG) | 0.4 | $5.2M | 180k | 28.79 |
|
|
| Urogen Pharma (URGN) | 0.4 | $5.1M | NEW | 400k | 12.70 |
|
| Monte Rosa Therapeutics (GLUE) | 0.4 | $4.9M | +4% | 930k | 5.30 |
|
| Geron Corporation (GERN) | 0.4 | $4.8M | NEW | 1.1M | 4.54 |
|
| Passage Bio (PASG) | 0.3 | $4.3M | 6.1M | 0.70 |
|
|
| Allogene Therapeutics (ALLO) | 0.3 | $4.2M | -31% | 1.5M | 2.80 |
|
| Prime Medicine (PRME) | 0.3 | $4.1M | +137% | 1.1M | 3.87 |
|
| Ventyx Biosciences (VTYX) | 0.3 | $3.8M | +31% | 1.7M | 2.18 |
|
| Zevra Therapeutics Com New (ZVRA) | 0.3 | $3.6M | NEW | 525k | 6.94 |
|
| Ardelyx (ARDX) | 0.3 | $3.4M | NEW | 500k | 6.89 |
|
| Ptc Therapeutics I (PTCT) | 0.2 | $3.0M | -11% | 80k | 37.10 |
|
| Penumbra (PEN) | 0.2 | $2.9M | NEW | 15k | 194.31 |
|
| Voyager Therapeutics (VYGR) | 0.2 | $2.9M | -18% | 490k | 5.85 |
|
| Macrogenics (MGNX) | 0.2 | $2.7M | +3% | 830k | 3.29 |
|
| Verve Therapeutics (VERV) | 0.2 | $2.5M | +5% | 525k | 4.84 |
|
| Intra Cellular Therapies (ITCI) | 0.2 | $2.2M | NEW | 30k | 73.17 |
|
| Establishment Labs Holdings Ord (ESTA) | 0.1 | $1.7M | NEW | 40k | 43.27 |
|
| Relmada Therapeutics (RLMD) | 0.1 | $1.6M | -59% | 490k | 3.24 |
|
| Achilles Therapeutics Sponsored Ads (ACHL) | 0.1 | $1.5M | 1.5M | 1.02 |
|
|
| Reneo Pharmaceuticals (RPHM) | 0.1 | $1.4M | +46% | 799k | 1.70 |
|
| Chimerix (CMRX) | 0.1 | $1.3M | 1.4M | 0.93 |
|
|
| Atara Biotherapeutics Com New (ATRA) | 0.1 | $1.0M | +11% | 125k | 8.13 |
|
| Tenax Therapeutics Com New (TENX) | 0.0 | $288k | NEW | 83k | 3.46 |
|
Past Filings by Vestal Point Capital
SEC 13F filings are viewable for Vestal Point Capital going back to 2024
- Vestal Point Capital 2024 Q3 filed Nov. 14, 2024
- Vestal Point Capital 2024 Q2 filed Aug. 14, 2024